Corporate Overview
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company’s portfolio consists of six commercialized products and multiple clinical and pre-clinical product candidates.

Six Commercial Products
- Pegvaliase for PKU
- Vosoritide for Achondroplasia
- Valoctocogene roxaparvovec for Hemophilia A
- BMN 250 for MPS IIIB, or Sanfilippo Type B
- BMN 290 for Friedreich’s Ataxia

General Company Information
- Founded in 1997
- IPO in 1999, NASDAQ ticker BMRN
- More than 2,500 employees worldwide
- Global sales in 70 markets worldwide

BioMarin at a Glance
- ~1000% Increase in revenues from 2007 to 2017
- Made the Forbes Most Innovative Companies list the past 4 years in a row
- 20th year of scientific innovation
- 6 FDA and EMA approved products
- 4 products currently in late-stage development
- 1st ERT therapy into the CNS via ICV delivery
- 5 years on average from IND to approval for all marketed products
- 176,072,261 shares outstanding
Financial Outlook

Actual and Estimated Revenue 2005-2018

- **Brineura**
- **Vimizim**
- **Naglazyme**
- **Kuvan**
- **Aldurazyme + Other**

(Revenues in millions)

<table>
<thead>
<tr>
<th>Year</th>
<th>Brineura</th>
<th>Vimizim</th>
<th>Naglazyme</th>
<th>Kuvan</th>
<th>Aldurazyme + Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005</td>
<td>$26</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2006</td>
<td>$84</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2007</td>
<td>$122</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2008</td>
<td>$297</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2009</td>
<td>$325</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2010</td>
<td>$376</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2011</td>
<td>$441</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2012</td>
<td>$501</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2013</td>
<td>$549</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2014</td>
<td>$751</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2015</td>
<td>$890</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016</td>
<td>$1,117</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2017</td>
<td>$1,313</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2018E</td>
<td>$1,470</td>
<td></td>
<td></td>
<td></td>
<td>$1,530</td>
</tr>
</tbody>
</table>

Full Year 2018 Revenue Guidance

($ in millions)

- **Total BioMarin Revenues**: Provided 2/22/18
  - $1,470 to $1,530
- **Vimizim**: $460 to $500
- **Naglazyme**: $325 to $355
- **Kuvan**: $440 to $480
- **Brineura**: $35 to $55

Selected Income Statement Guidance

($ in millions, except percentages)

- **Cost of Sales (% of Total Rev.)**: Provided 2/22/28
  - 20.0% to 21.0%
- **SG&A Expense**: $575 to $615
- **R&D Expense**: $645 to $685
- **Non-GAAP Net Income**: $100 to $140
- **GAAP Net Loss**: $(115) to $(165)

Executive Management

Jean-Jacques Bienaimé – Chairman and Chief Executive Officer
Hank Fuchs, M.D. – President, Worldwide Research and Development
Robert A. Baffi, Ph.D. – Executive Vice President, Technical Operations
Dan Spiegelman – Executive Vice President and Chief Financial Officer
Jeff Ajer – Executive Vice President and Chief Commercial Officer

Board of Directors

Jean-Jacques Bienaimé
Willard H. Dere, M.D.
Michael Grey
Elaine J. Heron, Ph.D.
Robert Hombach
V. Bryan Lawlis, Ph.D.
Alan J. Lewis, Ph.D.
Randy Meier
David Pyott
Dennis J. Slamon, M.D., Ph.D.

BioMarin Global Footprint

![Map showing BioMarin's global footprint with headquarters, regional offices, and manufacturing sites labeled. Information as of 4Q17.]